Stockreport

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis [Yahoo! Finance]

Equillium, Inc.  (EQ) 
Last equillium, inc. earnings: 3/26 04:07 pm Check Earnings Report
PDF Itolizumab continues to show clinically meaningful response in highly proteinuric subjects More than 80% of subjects achieved 50% reduction in urine protein creatinin [Read more]